Note (a): For the purposes of this section, systemic therapy is treatment that is administered through any route (orally, injection, suppository, intranasally) other than the skin, and topical therapy is treatment that is administered through the skin.
Note (b): Two or more skin conditions may be combined in accordance with § 4.25 only if separate areas of skin are involved. If two or more skin conditions involve the same area of skin, then only the highest evaluation shall be used.
Description | Rating |
---|---|
7805 Scars, other; and other effects of scars evaluated under diagnostic codes 7800, 7801, 7802, or 7804: | |
Evaluate any disabling effect(s) not considered in a rating provided under diagnostic codes 7800-04 under an appropriate diagnostic code | |
General Rating Formula For The Skin For DCs 7806, 7809, 7813-7816, 7820-7822, and 7824: | |
At least one of the following | 60 |
Characteristic lesions involving more than 40 percent of the entire body or more than 40 percent of exposed areas affected; or | |
Constant or near-constant systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen with long-wave ultraviolet-A light (PUVA), or other immunosuppressive drugs required over the past 12-month period | 60 |
At least one of the following | 30 |
Characteristic lesions involving 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected; or Systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period | |
At least one of the following | 10 |
Characteristic lesions involving at least 5 percent, but less than 20 percent, of the entire body affected; or | |
At least 5 percent, but less than 20 percent, of exposed areas affected; or | |
Intermittent systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of less than 6 weeks over the past 12-month period | |
No more than topical therapy required over the past 12-month period and at least one of the following | 0 |
Characteristic lesions involving less than 5 percent of the entire body affected; or | |
Characteristic lesions involving less than 5 percent of exposed areas affected | |
Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability. This rating instruction does not apply to DC 7824 |